Trial-Results center  
Clinical trial results database in 100 Feedback    Home


Related trials

TRA-2P TIMI 50, 2012 - vorapaxar vs placebo

CHARISMA, 2006 - clopidogrel + aspirin vs aspirin

Murphy, 2003 - roxifiban vs placebo

JAMIS, 1999 - aspirin vs placebo

CAPRIE, 1996 - clopidogrel vs aspirin

CAPRIE, 1996 - clopidogrel vs aspirin

SAPAT, 1992 - aspirin vs placebo

PARIS-II, 1986 - dipyridamol + aspirin vs placebo

Berglund, 1985 - ticlopidine vs placebo

GAMIS, 1980 - aspirin vs placebo

PARIS, 1980 - dipyridamol + aspirin vs placebo

AMIS, 1980 - aspirin vs placebo

PARIS, 1980 - dipyridamol + aspirin vs aspirin

PARIS, 1980 - aspirin vs placebo

Vogel, 1979 - aspirin vs placebo

Cardiff II, 1979 - aspirin vs placebo

CDPA, 1976 - aspirin vs placebo

Cardiff I, 1974 - aspirin vs placebo

Igloe, 1970 - dipyridamol vs placebo

Becker, 1967 - dipyridamol vs control

Atlanta (Sbar), 1967 - dipyridamol vs control

Wirecki, 1967 - dipyridamol vs control

Leiberman, 1964 - dipyridamol vs placebo

Neumann, 1964 - dipyridamol vs placebo

Kinsella, 1962 - dipyridamol vs placebo



See also:

  • All cardiovascular prevention clinical trials
  • All stable angina clinical trials
  • All coronary artery disease clinical trials
  • All clinical trials of death and events prevention
  • All clinical trials of clopidogrel
  •  

    ASCET study,

    [NCT00222261] Preliminary results download pdf: clopidogrel | antithrombotics for stable angina

    Treatments

    Studied treatment clopidogrel 75 mg once daily for two years
    Control treatment Aspirin 160 mg once daily for two years

    Patients

    Patients patients with documented coronary heart disease and treated with aspirin
    Remarks platelet function was also assessed at randomization with the PFA100 method and platelet aggregometry

    Method and design

    Randomized effectives 498 / 503 (studied vs. control)
    Design Parallel groups
    Blinding open
    Hypothesis Superiority
    Primary endpoint all-cause death, nonfatal MI, ischemic stroke, and unstable angina


    Results

    Endpoint Studied treat.
    n/N
    Control treat.
    n/N
    Graph RR [95% CI]

    cardiovascular events

    50 / 498
    56 / 503
    0,90 [0,63;1,29]
    0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial
    Ref
    Studied treat. Control treat.
    cardiovascular events 50 / 498 (10,0%) 56 / 503 (11,1%) 0,90 [0,63;1,29] all-cause death, nonfatal MI, ischemic stroke, and unstable angina 
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:

    Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    cardiovascular events 10,04% 11,13% -10,9‰

    Meta-analysis of all similar trials:

    antiplatelets drug in cardiovascular prevention for secondary prevention in patients with CAD

    antithrombotics in stable angina for all type of patient

    death and events prevention in coronary artery disease for all type of patients



    Reference(s)

    Trials register # NCT00222261

    (c) 2004-2014 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend

    100100